Lara N Roberts Selected Research

Hemostatics (Antihemorrhagics)

12/2023	How to manage hemostasis in patients with liver disease during interventions.
1/2023	The ISTH SSC Subcommittee on Hemostatic Management of Patients with Liver Disease: goals, ambitions, and call for collaboration.
1/2023	The ISTH SSC subcommittee on Hemostatic Management of Patients with Liver Disease: goals, ambitions, and call for collaboration: reply.
1/2022	Periprocedural management of abnormal coagulation parameters and thrombocytopenia in patients with cirrhosis: Guidance from the SSC of the ISTH.
12/2021	Rebalanced hemostasis in liver disease: a misunderstood coagulopathy.
1/2021	Treatment of bleeding in patients with liver disease.
1/2021	Prophylactic fresh frozen plasma and platelet transfusion have a prothrombotic effect in patients with liver disease.
9/2020	Incidence of Bleeding and Thrombosis in Patients with Liver Disease.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Lara N Roberts Research Topics

Disease

11	Hemorrhage 12/2023 - 02/2010
9	Venous Thromboembolism 07/2022 - 05/2010
7	Liver Diseases (Liver Disease) 01/2023 - 05/2014
5	Fibrosis (Cirrhosis) 10/2022 - 01/2020
5	Thrombosis (Thrombus) 07/2022 - 01/2018
5	COVID-19 01/2022 - 09/2020
5	Venous Thrombosis (Deep-Vein Thrombosis) 10/2016 - 01/2013
4	Thrombocytopenia (Thrombopenia) 12/2023 - 01/2021
4	Stroke (Strokes) 12/2021 - 01/2016
3	Menorrhagia 03/2023 - 04/2016
3	Atrial Fibrillation 12/2021 - 01/2018
3	Thrombophilia 09/2020 - 01/2016
2	Acute Liver Failure (Fulminant Hepatic Failure) 09/2020 - 05/2014
2	Myeloproliferative Disorders (Myeloproliferative Disorder) 07/2012 - 01/2009
1	End Stage Liver Disease 05/2023
1	Thromboinflammation 07/2022
1	Hemophilia A (Haemophilia) 07/2022
1	Disease Susceptibility (Diathesis) 12/2021
1	Portal Hypertension 09/2020
1	Multiple Myeloma 08/2019
1	Uterine Hemorrhage (Uterine Bleeding) 11/2018
1	Overweight 10/2017
1	Body Weight (Weight, Body) 10/2017
1	Embolic Stroke 01/2016
1	Ischemic Stroke 01/2016
1	Infections 07/2015
1	Budd-Chiari Syndrome (Budd Chiari Syndrome) 07/2012
1	Thromboembolism 01/2009
1	Peripheral Vascular Diseases (Peripheral Vascular Disease) 01/2009
1	Thrombocytosis (Thrombocythemia) 01/2009

Drug/Important Bio-Agent (IBA)

13	AnticoagulantsIBA 05/2023 - 05/2010
8	Hemostatics (Antihemorrhagics)IBA 12/2023 - 09/2020
8	Thrombin FDA Link 01/2021 - 02/2010
5	RivaroxabanIBA 01/2022 - 04/2016
5	fibrin fragment D (D-dimer)IBA 11/2020 - 03/2013
3	Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)IBA 01/2021 - 01/2018
2	Fibrinogen (Factor I)FDA Link 01/2021 - 06/2016
2	Vitamin K FDA Link 11/2018 - 07/2018
2	Janus Kinase 2IBA 07/2012 - 01/2009
1	VaccinesIBA 07/2022
1	Protein CIBA 12/2021
1	Warfarin (Coumadin)FDA LinkGeneric 01/2021
1	Heparin (Liquaemin)FDA LinkGeneric 01/2021
1	4- ((1,4,8,11- tetraazacyclotetradec- 1- yl)methyl)benzoic acidIBA 11/2020
1	Tranexamic Acid (AMCA)FDA Link 10/2020
1	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 08/2019
1	apixabanIBA 08/2019
1	Factor VIII (Coagulation Factor VIII)IBA 01/2016

Therapy/Procedure

5	Therapeutics 10/2021 - 01/2009
2	Platelet Transfusion (Blood Platelet Transfusions) 12/2023 - 01/2021
2	Secondary Prevention 12/2021 - 01/2018
2	Liver Transplantation 09/2020 - 07/2012
2	Thrombolytic Therapy 06/2016 - 01/2016
1	Contraindications 10/2022
1	Length of Stay 01/2022
1	Critical Care (Surgical Intensive Care) 11/2020
1	Renal Replacement Therapy (Therapies, Renal Replacement) 09/2020